[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659690":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":21,"studyPopulation":13,"armGroups":22,"interventions":46,"overallOfficials":52,"centralContacts":56,"locations":65,"responsibleParty":84,"collaborators":86,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":91,"sex":97,"minAge":98,"maxAge":13,"enrollmentInfo":99,"targetDuration":13,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":13,"overallStatus":67,"whyStopped":13,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Grand Hôpital de Charleroi","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"To validate and accredit the TST79 test on plasma samples within the hospital's pathology laboratory","The aim is to extend tumour DNA sequencing to circulating tumour DNA (ctDNA), which is present in the plasma of cancer patients.","Through study completion, an average of two years",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":17,"primaryPurpose":18,"observationalModel":13,"timePerspective":13,"maskingInfo":19},"NON_RANDOMIZED","PARALLEL","Patients will be included based on the criteria relating to their mutations, which can be validated by the TST79 test.","DIAGNOSTIC",{"masking":20,"maskingDescription":13,"whoMasked":13},"NONE","The development of targeted therapies in oncology requires the regular implementation of new tests. Routine clinical analyses currently focus mainly on tumour tissue, but analyses of blood components - particularly plasma - or other biological fluids from patients with cancer are gaining clinical significance in light of advances in molecular biology techniques and knowledge in oncology.\n\nThe laboratory wishes to offer patients with cancer sequencing of circulating free DNA (ctDNA) in plasma using a commercial test developed by Illumina. This test can detect various types of mutations (point mutations, small deletions or insertions, loss or gain of gene copy number, and gene fusions) in 79 genes (TST79 test).",[23,28,31,34,37,40,43],{"label":24,"type":25,"description":13,"interventionNames":26},"2 patients with POLE-mutated endometrial cancer","EXPERIMENTAL",[27],"Genetic: Gene-alteration pair (G-A)",{"label":29,"type":25,"description":13,"interventionNames":30},"2-4 patients with lung adenocarcinoma involving rare gene fusions",[27],{"label":32,"type":25,"description":13,"interventionNames":33},"1-2 patients with lung adenocarcinoma with a point mutation in EGFR",[27],{"label":35,"type":25,"description":13,"interventionNames":36},"2-3 patients with GIST (gastrointestinal stromal tumour) harbouring a KIT mutation",[27],{"label":38,"type":25,"description":13,"interventionNames":39},"2-3 patients with clear-cell renal cell carcinoma with a VHL mutation",[27],{"label":41,"type":25,"description":13,"interventionNames":42},"1-2 patients with breast cancer with ERBB2 amplification",[27],{"label":44,"type":25,"description":13,"interventionNames":45},"2-3 patients with high-grade ovarian carcinoma and a BRCA1 or BRCA2 mutation",[27],[47],{"type":48,"name":49,"description":50,"armGroupLabels":51,"otherNames":13},"GENETIC","Gene-alteration pair (G-A)","Point mutations, small insertions or deletions (indels), gene fusions, copy number amplifications.",[41,32,24,35,38,44,29],[53],{"name":54,"affiliation":5,"role":55},"David Schröder, MD, PhD","PRINCIPAL_INVESTIGATOR",[57,62],{"name":54,"role":58,"phone":59,"phoneExt":60,"email":61},"CONTACT","0032 60","110089","david.schroder@ghdc.be",{"name":63,"role":58,"phone":59,"phoneExt":60,"email":64},"Aline Gillain, MedSciences","aline.gillain@ghdc.be",[66],{"facility":5,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"RECRUITING","Charleroi","Hainaut","6060","Belgium","BE",{"type":74,"coordinates":75},"Point",[76,77],4.44448,50.41136,{"lat":77,"lon":76},[80,81,83],{"name":54,"role":58,"phone":59,"phoneExt":60,"email":61},{"name":82,"role":58,"phone":59,"phoneExt":60,"email":64},"Aline Gillain, MedSC",{"name":54,"role":55,"phone":13,"phoneExt":13,"email":13},{"type":85,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR",[87],{"name":88,"class":6},"Institut de Pathologie et de Génétique Charleroi","100659690","blood-samples-were-taken-from-patients-undergoing-oncological-treatment-in-order-to-validate-the-tst79-molecular-test-100659690",false,"NCT07868640","Blood Samples Were Taken From Patients Undergoing Oncological Treatment in Order to Validate the TST79 Molecular Test","Blood Samples Were Taken From Patients Undergoing Oncological Treatment in Order to Validate the TST79 Molecular Test at the Department of Pathology at the Grand Hôpital de Charleroi.","OncoSang-TST79","Inclusion Criteria:\n\n* Patients with the following types of cancer may be invited to donate blood as part of one of two approaches:\n* lung adenocarcinoma\n* colorectal adenocarcinoma\n* breast carcinoma\n* prostate adenocarcinoma\n* clear cell renal cell carcinoma\n* GIST\u002Fgastrointestinal stromal tumour\n* melanoma\n* urothelial carcinoma\n* endometrial carcinoma\n* high-grade ovarian carcinoma","ALL","18 Years",{"count":100,"type":101},15,"ESTIMATED","INTERVENTIONAL",[104],"NA","The pathological anatomy laboratory, which is managed by the IPG, would involve monitoring patients being treated for cancer and receiving care at the GHDC in order to take blood samples from those in whom the presence of plasma ctDNA carrying a mutation in a specific gene is suspected - a mutation detectable by the TST79 test.",[107],"Cancer","2026-10-06",{"date":110,"type":111},"2026-10-09","ACTUAL",{"date":113,"type":111},"2026-09-15",{"date":115,"type":101},"2028-12-30",{"name":5,"class":6},1]